决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Rational Engineering of Notch1 Signaling to Boost the Proliferation of CD19-BBζ CAR-T.
Rational Engineering of Notch1 Signaling to Boost the Proliferation of CD19-BBζ CAR-T.
我们的研究结果证明了 Notch1 在 CAR-T 效应功能中的关键作用,并提供了一种通过利用天然基因调控来增强内源性 Notch1 活性的新策略。
靶向 CD19 的 CAR T 细胞彻底改变了复发/难治性 B 细胞恶性肿瘤的治疗。然而,大约50%的患者会复发。患者数据表明 CD19+ 复发与 CAR T 细胞增殖和/或持久性较差有关。我们的目标是通过操纵Notch1来提高CD19-CAR T细胞的存活率,Notch1是一种在T细胞受体连接后被激活的受体,对于上调T细胞中的促炎和存活基因至关重要。然而,它在 CAR T 细胞中的作用仍然知之甚少。我们发现Notch1胞内结构域(N1ICD)的慢病毒过表达和Notch1基因敲除都会导致CAR-T细胞活化和增殖缺陷。这表明 CAR T 细胞需要精确、平衡水平的 Notch1 信号传导才能实现强大的效应功能。 PEST 结构域位于 Notch1 胞内结构域的最远端 C 末端,通过泛素化调节受体的半衰期。为了增强活性 Notch1 的水平并延长受体信号传导,我们从基因上删除了 CAR T 细胞内源性 N1ICD 中的这个结构域。 Notch1 PEST 缺失的 CAR T 细胞在激活后表现出增强的增殖,导致体外针对 CD19+ 肿瘤的细胞毒性增加。转录方面,Notch1 PEST 缺失导致 CAR 激活期间干扰素反应途径和增殖基因上调,这与 Notch1 激活一致。在 B-ALL 异种移植体内模型中,与对照 CAR T 细胞相比,使用 Notch1 PEST 缺失的 CAR T 细胞治疗可实现更大的肿瘤缩小和 CAR-T 扩增增加。我们的研究结果证明了 Notch1 在 CAR-T 效应器功能中的关键作用,并提供了一种利用天然基因调控增强内源性 Notch1 活性的新策略。
CAR T-cells targeting CD19 have revolutionized the treatment of relapsed/refractory B-cell malignancies. However, approximately 50% of patients relapse. Patient-derived data indicates that CD19+ relapse is linked to poor CAR T-cell proliferation and/or persistence. We aimed to improve CD19-CAR T-cell survival by manipulating Notch1, a receptor that is activated following T-cell receptor ligation and is essential for upregulating pro-inflammatory and survival genes in T-cells. However, its role in the context of CAR T-cells remains poorly understood. We found that both lentiviral overexpression of Notch1's intracellular domain (N1ICD) and Notch1 genetic knockout resulted in defective CAR-T cell activation and proliferation. This suggests that CAR T-cells require a precise, balanced level of Notch1 signaling for strong effector function. The PEST domain, located at the most distal C-terminus of the Notch1 intracellular domain, regulates the receptor's half-life through ubiquitylation. To augment the levels of active Notch1 and prolong the receptor's signaling, we genetically deleted this domain in the endogenous N1ICD of CAR T-cells. Notch1 PEST-deleted CAR T-cells showed enhanced proliferation post-activation, leading to increased cytotoxicity against CD19+ tumors in vitro. Transcriptionally, Notch1 PEST deletion resulted in upregulation of interferon response pathways and proliferative genes during CAR activation, consistent with Notch1 activation. In B-ALL xenograft in vivo models, treatment with Notch1 PEST-deleted CAR T-cells resulted in greater tumor reduction and increased CAR-T expansion compared to control CAR T-cells. Our findings demonstrate a critical role of Notch1 in CAR-T effector function and provide a novel strategy to augment endogenous Notch1 activity by leveraging native gene regulation.
MEMBER ACCOUNT
登录成功会直接打开下一页。